Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy

被引:9
|
作者
Fantini, Massimo [1 ]
Arlen, Philip Martin [1 ]
Tsang, Kwong Yok [1 ]
机构
[1] Precis Biol Inc, Bethesda, MD 20814 USA
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
NK cells; ADCC; modulatory cytokines; adoptive NK cell therapy; monoclonal antibody; CAR-NK; LONG-TERM SAFETY; METASTATIC UROTHELIAL CARCINOMA; GAMMA-RIIIA POLYMORPHISMS; C-RECEPTOR POLYMORPHISMS; PHASE-I; COLORECTAL-CANCER; CORD BLOOD; MEDIATED CYTOTOXICITY; IMMUNE-SYSTEM; SOLUBLE MICA;
D O I
10.3389/fimmu.2023.1275904
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment and expansion of immune suppressor cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), modulation of ligands for NK cells receptors. Several strategies have been developed to enhance the antitumor activity of NK cells with the goal of overcoming cancer cells resistance to NK cells. The three main strategies to engineer and boost NK cells cytotoxicity include boosting NK cells with modulatory cytokines, adoptive NK cell therapy, and the employment of engineered NK cells to enhance antibody-based immunotherapy. Although the first two strategies improved the efficacy of NK cell-based therapy, there are still some limitations, including immune-related adverse events, induction of immune-suppressive cells and further cancer resistance to NK cell killing. One strategy to overcome these issues is the combination of monoclonal antibodies (mAbs) that mediate ADCC and engineered NK cells with potentiated anti-cancer activity. The advantage of using mAbs with ADCC activity is that they can activate NK cells, but also favor the accumulation of immune effector cells to the tumor microenvironment (TME). Several clinical trials reported that combining engineered NK cells with mAbs with ADCC activity can result in a superior clinical response compared to mAbs alone. Next generation of clinical trials, employing engineered NK cells with mAbs with higher affinity for CD16 expressed on NK cells, will provide more effective and higher-quality treatments to cancer patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Selection and expansion of natural killer cells for NK cell-based immunotherapy
    Petra S. A. Becker
    Garnet Suck
    Paulina Nowakowska
    Evelyn Ullrich
    Erhard Seifried
    Peter Bader
    Torsten Tonn
    Christian Seidl
    Cancer Immunology, Immunotherapy, 2016, 65 : 477 - 484
  • [2] Selection and expansion of natural killer cells for NK cell-based immunotherapy
    Becker, Petra S. A.
    Suck, Garnet
    Nowakowska, Paulina
    Ullrich, Evelyn
    Seifried, Erhard
    Bader, Peter
    Tonn, Torsten
    Seidl, Christian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (04) : 477 - 484
  • [3] Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy
    Murugan, Dhanashree
    Murugesan, Vasanth
    Panchapakesan, Balaji
    Rangasamy, Loganathan
    CANCERS, 2022, 14 (21)
  • [4] Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
    Liu, Pingyi
    Chen, Lingling
    Zhang, Haiyan
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [5] Natural Killer cell-based cancer immunotherapy for rhabdomyosarcoma
    Rossi, Gustavo Rodrigues
    Lam, Pui Yeng
    Omer, Natacha
    Tu, Cui
    Souza-Fonseca-Guimaraes, Fernando
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [6] Natural killer T cell-based cancer immunotherapy
    van der Vliet, Hans J. J.
    Balk, Steven P.
    Exley, Mark A.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 5921 - 5923
  • [7] Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
    Cheng Sun
    Hao-yu Sun
    Wei-hua Xiao
    Cai Zhang
    Zhi-gang Tian
    Acta Pharmacologica Sinica, 2015, 36 : 1191 - 1199
  • [8] Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
    Sun, Cheng
    Sun, Hao-yu
    Xiao, Wei-hua
    Zhang, Cai
    Tian, Zhi-gang
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (10) : 1191 - 1199
  • [9] Immunosenescence: limitations of natural killer cell-based cancer immunotherapy
    Tarazona, Raquel
    Sanchez-Correa, Beatriz
    Casas-Aviles, Ignacio
    Campos, Carmen
    Pera, Alejandra
    Morgado, Sara
    Lopez-Sejas, Nelson
    Hassouneh, Fakhri
    Bergua, Juan M.
    Jose Arcos, Maria
    Banas, Helena
    Casado, Javier G.
    Duran, Esther
    Labella, Fernando
    Solana, Rafael
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (02) : 233 - 245
  • [10] Invariant natural killer T cell-based immunotherapy for cancer
    Motohashi, Shinichiro
    Nakayama, Toshinori
    IMMUNOTHERAPY, 2009, 1 (01) : 73 - 82